MAPT and Alzheimer disease: Numerous studies have consistently shown a marked increase in CSF total tau and phosphorylated tau accompanied by a reduction in amyloid-β1–42 in Alzheimer’s disease, and also in the mild cognitive impairment (MCI) stage of the disease [2, 3].